HEALTH

SCA introduces Tena Ultra Thins

BY Michael Johnsen

PHILADELPHIA SCA Personal Care North America on Wedneseday introduced a new category of adult absorbent products with the launch of the first Ultra Thin pads for moderate and heavy bladder protection.

Available in the United States and in Canada, the new Tena brand Ultra Thins reflect the company’s dedication to improve the quality of life for the more than one in four women above the age of 40 affected by bladder weakness.

On shelves this month, the Tena Ultra Thins were designed after consumer research identified that women suffering from moderate to heavy bladder weakness craved the option of discreet protection, but were not willing to move to a thinner pad because of the fear of leaks. TENA Ultra Thins’ unique airlaid core technology offers women the same security and odor absorption as thicker pads, in a thin and discreet product.

To support the introduction of Tena Ultra Thins, SCA will announce a number of partnerships that will expand its BladderTalk campaign, which was launched in the United States in June of 2009. The campaign’s goal is to evolve the dialogue around bladder weakness and engage, educate and empower women to bring this common condition out of the closet. This year, the company will bring this program to Canada with a series of awareness and advocacy efforts to inform women and break the taboo. The BladderTalk national survey of women suffering from bladder weakness found that nearly 40% of women with the condition across the U.S. and Canada refuse to talk about it with anyone.

In addition to the partnerships, SCA will expand its North American Evolution advertising campaign, launched in August 2009 to educate women about the latest evolution in moderate and severe bladder protection products.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

CVS/pharmacy to carry Reed’s Rx line

BY Michael Johnsen

LOS ANGELES Beverage supplier Reed’s on Tuesday announced that CVS/pharmacy has agreed to carry the new Reed’s Rx line in the digestive/stomach aisles.

Reed’s Rx products are ginger-based remedies for nausea and motion sickness.

“Consumers have been using our natural products for morning sickness and motion sickness for years,” stated Chris Reed, Reed’s chairman and CEO. “We have found a lot of exciting research and historical evidence pointing to ginger as an effective remedy for nausea throughout history, some dating back as far as the early Roman Empire,” he said. “CVS is cutting edge in its offerings and has been integrating natural alternatives into their stores for quite some time,” Reed added. 

Reed’s announced the launch of the nausea relief beverages earlier this month.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

HEALTH

Quigley, Phosphagenics form Phusion Laboratories

BY Michael Johnsen

DOYLESTOWN, Pa. The Quigley Corp. and Phosphagenics Limited on Tuesday announced the formation of a joint venture, to be called Phusion Labs, to develop nonprescription remedies.

The new products will be powered by Phosphagenics’ proprietary, patented TPM technology, a delivery technology that increases the amount and depth of penetration of active molecules into the skin, the companies stated.

“Phosphagenics’ … technology lends itself perfectly to delivery of OTC drugs, as the inclusion of TPM will increase the absorption and efficacy of many OTC active ingredients,” stated Quigley CEO Ted Karkus. “Our signature product Cold-Eeze has built its reputation and robust distribution network on its uniquely effective delivery system. We see the world-class scientific research team at Phosphagenics as the perfect partner to help us leverage our existing network and consumer product expertise.”

Under the terms of the agreement, Quigley and Phosphagenics each will own 50% of Phusion Labs. Quigley will make a one-time payment to Phosphagenics of $1 million and the issuance to Phosphagenics of 1.4 million shares of Quigley common stock.

Additionally, Quigley has contributed $500,000 of initial capital and committed up to $2 million toward the initial development and marketing costs of new products for Phusion Labs. Quigley will oversee distribution, sales and marketing of the new products.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES